Aeglea BioTherapeutics, Inc., a biotechnology company developing enzyme-based therapeutics to treat rare genetic diseases and cancer, has entered into a clinical collaboration agreement with Merck to evaluate the combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the treatment of patients with small cell lung cancer (SCLC). “Earlier this year, we selected SCLC as one of the single agent expansion arms for our ongoing Phase I trial ba...